The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).
 
Maeve Aine Lowery
No Relationships to Disclose
 
David Paul Kelsen
No Relationships to Disclose
 
Sloane C. Smith
No Relationships to Disclose
 
Malcolm Moore
No Relationships to Disclose
 
Hedy Lee Kindler
No Relationships to Disclose
 
Talia Golan
No Relationships to Disclose
 
Amiel Segal
No Relationships to Disclose
 
Ellen Hollywood
No Relationships to Disclose
 
Hannah Maynard
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Mary Ellen Moynahan
No Relationships to Disclose
 
Anne Fusco
No Relationships to Disclose
 
Zsofia Kinga Stadler
No Relationships to Disclose
 
Kinh G Do
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose
 
Kenneth H. Yu
No Relationships to Disclose
 
Laura H. Tang
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics (I)
Research Funding - Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst)